<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00331812</url>
  </required_header>
  <id_info>
    <org_study_id>CHU63-0007</org_study_id>
    <nct_id>NCT00331812</nct_id>
  </id_info>
  <brief_title>Mitochondrial Functions and Oxidative Stress in ALS Patients</brief_title>
  <official_title>Study of Mitochondrial Functions and Oxidative Stress in ALS Patients.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Clermont-Ferrand</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University Hospital, Limoges</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Institut National de la Recherche Agronomique</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Clermont-Ferrand</source>
  <brief_summary>
    <textblock>
      In Amyotrophic Lateral Sclerosis (ALS), malnutrition is frequent (16 to 50 % of the patients)
      and is an independent prognostic factor. One of the implicated factors is the increase of
      resting energy expenditure (REE) which can be found in about 50 % of ALS patients. The origin
      of this hypermetabolism is currently unknown but could be located in the mitochondria. In
      fact, some studies have found mitochondrial abnormalities and the existence of an oxidative
      stress. Thus, the aim of this study is to characterize the mitochondrial abnormalities and
      the oxidant/antioxidant status of ALS patients and to determine their relationship with the
      metabolic status, hypermetabolism or normometabolism. Three groups of patients will be
      studied : 20 hypermetabolic ALS patients, 20 normometabolic ALS patients and 20 healthy
      volunteers paired for age and sex.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In Amyotrophic Lateral Sclerosis (ALS), malnutrition is frequent (16 to 50 % of the patients)
      and is an independent prognostic factor. One of the implicated factors is the increase of
      resting energy expenditure (REE) which can be found in about 50 % of ALS patients. The origin
      of this hypermetabolism is currently unknown but could be located in the mitochondria. In
      fact, some studies have found mitochondrial abnormalities and the existence of an oxidative
      stress. Thus, the aim of this study is to characterize the mitochondrial abnormalities and
      the oxidant/antioxidant status of ALS patients and to determine their relationship with the
      metabolic status, hypermetabolism or normometabolism. Three groups of patients will be
      studied : 20 hypermetabolic ALS patients, 20 normometabolic ALS patients and 20 healthy
      volunteers paired for age and sex.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>February 2006</start_date>
  <completion_date type="Anticipated">February 2008</completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>relationship between these abnormalities and the metabolic status (hypermetabolism or normometabolism).</measure>
  </primary_outcome>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Amyotrophic Lateral Sclerosis</condition>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Mitochondrial functions and oxidative stress</intervention_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Three groups of patients will be studied : 20 hypermetabolic ALS patients, 20
        normometabolic ALS patients and 20 healthy volunteers paired for age and sex.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  male or female

          -  age &gt; 30 years

          -  definite or probable ALS according to the El Escorial criteria, bulbar or spinal form,
             ALS diagnosis &lt; 1 year and treatment by riluzole.

        Exclusion Criteria:

          -  family history of ALS,

          -  oral, enteral or parenteral nutritional supply,

          -  vitamin or trace element supplementation

          -  confusing illness (cancer, diabetes, chronic infectious or inflammatory
             disease,thyroid disorders, recent surgery...),

          -  current tobacco use,

          -  alcoholism

          -  treatment by corticosteroids,

          -  diuretics,

          -  anorectics

          -  NSAIDs

          -  cytotoxics

          -  anticoagulants...
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Corinne Bouteloup, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Clermont-Ferrand</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Corinne Bouteloup, Dr</last_name>
    <phone>(+33) 04 73 75 05 04</phone>
    <email>cbouteloup@chu-clermontferrand.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Clermont-Ferrand University Hospital</name>
      <address>
        <city>Clermont-Ferrand</city>
        <state>Auvergne</state>
        <zip>63000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Desport JC, Preux PM, Magy L, Boirie Y, Vallat JM, Beaufr√®re B, Couratier P. Factors correlated with hypermetabolism in patients with amyotrophic lateral sclerosis. Am J Clin Nutr. 2001 Sep;74(3):328-34.</citation>
    <PMID>11522556</PMID>
  </reference>
  <reference>
    <citation>Ferrante RJ, Browne SE, Shinobu LA, Bowling AC, Baik MJ, MacGarvey U, Kowall NW, Brown RH Jr, Beal MF. Evidence of increased oxidative damage in both sporadic and familial amyotrophic lateral sclerosis. J Neurochem. 1997 Nov;69(5):2064-74.</citation>
    <PMID>9349552</PMID>
  </reference>
  <reference>
    <citation>Menzies FM, Ince PG, Shaw PJ. Mitochondrial involvement in amyotrophic lateral sclerosis. Neurochem Int. 2002 May;40(6):543-51. Review.</citation>
    <PMID>11850111</PMID>
  </reference>
  <verification_date>January 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 23, 2006</study_first_submitted>
  <study_first_submitted_qc>May 30, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 31, 2006</study_first_posted>
  <last_update_submitted>January 18, 2011</last_update_submitted>
  <last_update_submitted_qc>January 18, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 19, 2011</last_update_posted>
  <responsible_party>
    <name_title>Dr Corinne BOUTELOUP</name_title>
    <organization>CHU Clermont-Ferrand</organization>
  </responsible_party>
  <keyword>Hypermetabolism</keyword>
  <keyword>Mitochondrial abnormalities</keyword>
  <keyword>Oxidant/antioxidant status</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Motor Neuron Disease</mesh_term>
    <mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

